3-{5-[2-(Trifluoromethoxy)phenyl]-2-furyl}acrylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-{5-[2-(Trifluoromethoxy)phenyl]-2-furyl}acrylic acid
• 英文别名: (E)-3-[5-[2-(trifluoromethoxy)phenyl]furan-2-yl]prop-2-enoic acid
• 化学式: C₁₄H₉F₃O₄
• 分子量: 298.21
• InChiKey: NZKLTODPPZSQAT-SOFGYWHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  59.7
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
  申请人：sanofi-aventis

  公开号：EP1939180A1

  公开（公告）日：2008-07-02

  The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及式I的杂环丙烯酰胺， 其中Het、X、Ra、Rb、R1、R2和R3具有权利要求中所示的含义，这些化合物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备式I化合物的方法，包括它们的药物组合物，以及利用式I化合物制造用于刺激内皮型一氧化氮合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：STROBEL Hartmut

  公开号：US20100016272A1

  公开（公告）日：2010-01-21

  The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, R a , R b , R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及式I的杂环基丙烯酰胺，其中Het、X、Ra、Rb、R1、R2和R3具有声明中指示的含义，这些化合物调节内皮型一氧化氮（NO）合成酶的转录，是有价值的药理活性化合物。具体来说，式I的化合物上调内皮型NO合成酶的表达，可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备式I的化合物的过程，包括它们的制药组合物，以及使用式I的化合物制造用于刺激内皮型NO合成酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化，血栓形成，冠状动脉疾病，高血压和心脏功能不全等。
• US8304438B2
  申请人：——

  公开号：US8304438B2

  公开（公告）日：2012-11-06
• [EN] HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] HÉTÉROARYLACRYLAMIDES ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2008074413A2

  公开（公告）日：2008-06-26

  [EN] The present invention relates to heteroarylacrylamides of the formula (I), in which Het, X, R^a, R^b, R¹, R² and R³ have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula (I) upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula (I), to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
  [FR] La présente invention concerne des hétéroarylacrylamides de formule (I), dans laquelle Het, X, R^a, R^b, R¹, R² et R³ ont les significations indiquées dans les revendications, modulant la transcription de l'oxyde nitrique (NO) synthase endothéliale et sont des composés pharmacologiquement actifs intéressants. De manière spécifique, les composés de formule (I) régulent à la hausse l'expression de l'enzyme NO synthase endothéliale et peuvent être appliqués dans des affections dans lesquelles une augmentation de l'expression de ladite enzyme ou une augmentation du taux de NO ou la normalisation d'une diminution du taux de NO est souhaitée. L'invention concerne en outre des procédés de préparation de composés de formule (I), des compositions pharmaceutiques les comprenant et l'utilisation de composés de formule I pour la fabrication d'un médicament destiné à la stimulation de l'expression de la NO synthase endothéliale ou au traitement de diverses maladies y compris des troubles cardiovasculaires tels que l'athérosclérose, la thrombose, la coronaropathie, l'hypertension et l'insuffisance cardiaque, par exemple.